1-4 of 4
James Weitzman
Close
Sort by
Journal Articles

Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphomas: Final Results from a Phase 1-2 Trial

Jeremy S. Abramson, MD, Eric D. Jacobsen, MD, Robert Allyn Redd, MS, Tak Takvorian, MD, David C. Fisher, MD, Jennifer R. Brown, Joel H Schwartz, MD, James Weitzman, MD, Donna Neuberg, ScD, Jeffrey A. Barnes, MD PhD, Ephraim P Hochberg, MD
Journal: Blood
Blood (2014) 124 (21): 4423.
https://doi.org/10.1182/blood.V124.21.4423.4423
Published: 2014
Journal Articles

Ofatumumab As Initial Therapy For Indolent B Cell Lymphomas: A Phase II Trial

Jeffrey A. Barnes, MD, PhD, Yang Feng, PhD, Ephraim P Hochberg, MD, Tak Takvorian, MD, James Weitzman, MD, David C. Fisher, MD, Eric D. Jacobsen, MD, Robin Joyce, MD, Donna S. Neuberg, ScD, Jeremy S. Abramson, MD
Journal: Blood
Blood (2013) 122 (21): 3062.
https://doi.org/10.1182/blood.V122.21.3062.3062
Published: 2013
Journal Articles

Transfection with mRNA for CD19 Specific Chimeric Antigen Receptor Restores Natural Killer Cell Mediated Killing of CLL Cells.

Laurent Boissel, PhD, Monica Betancur, M.Sc., Hande Tuncer, M.D., James Weitzman, M.D., Hans Klingemann, M.D., Ph.D.
Journal: Blood
Blood (2007) 110 (11): 3110.
https://doi.org/10.1182/blood.V110.11.3110.3110
Published: 2007
Journal Articles

Variable Contribution of Different Monocloncal Antibodies to NK Cell-Mediated ADCC Against Primary CLL Cells.

James Weitzman, Monica Betancur, Laurent Boissel, Arthur P. Rabinowitz, Hans Klingemann
Journal: Blood
Blood (2007) 110 (11): 4715.
https://doi.org/10.1182/blood.V110.11.4715.4715
Published: 2007